Literature DB >> 24877975

Worldwide incidence of cervical lesions: a systematic review.

J Ting1, A F Rositch2, S M Taylor3, L Rahangdale4, H M Soeters5, X Sun5, J S Smith5.   

Abstract

We conducted a systematic review summarizing data on incidence of high- and low-grade lesions in women with normal baseline cervical cytology, stratified by age (<30 and ⩾30 years), and baseline human papillomavirus (HPV) infection. Incidence of high- and low-grade lesions in women aged ⩾30 years with a baseline HPV infection increased over follow-up time (5-127 months), although incidence generally remained <10%. Without baseline HPV infection, incidence of high-grade lesions remained low over follow-up time (<5% over 5-122 months). Incidence of high-grade lesions in women aged ⩾30 years with baseline HPV infection appeared similar to that in women aged <30 years. In some women aged <30 years, high-grade lesions can develop relatively shortly after initial HPV infection. We observed an increase in low-grade lesions over time in women aged ⩾30 years with baseline HPV infection, potentially indicative of an HPV infection that is potentially progressing to higher grade lesions.

Entities:  

Mesh:

Year:  2014        PMID: 24877975      PMCID: PMC9206785          DOI: 10.1017/S0950268814001356

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  82 in total

1.  Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status.

Authors:  H S Mitchell
Journal:  Cancer       Date:  2001-08-25       Impact factor: 6.860

2.  Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears.

Authors:  A B Bos; M van Ballegooijen; M E van den Akker-van Marle; A G Hanselaar; G J van Oortmarssen; J D Habbema
Journal:  Am J Clin Pathol       Date:  2001-06       Impact factor: 2.493

3.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  Am J Clin Pathol       Date:  2012-04       Impact factor: 2.493

4.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

Authors: 
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

5.  The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

Authors:  J J Carter; L A Koutsky; G C Wipf; N D Christensen; S K Lee; J Kuypers; N Kiviat; D A Galloway
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

6.  Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions.

Authors:  C Clavel; M Masure; M Levert; I Putaud; C Mangeonjean; M Lorenzato; P Nazeyrollas; R Gabriel; C Quereux; P Birembaut
Journal:  Diagn Mol Pathol       Date:  2000-09

7.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.

Authors:  Cosette M Wheeler; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Margaret James; Scott Vuocolo; Teresa M Hesley; Eliav Barr
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

Review 8.  Human papillomavirus and cervical cancer.

Authors:  Mark Schiffman; Philip E Castle; Jose Jeronimo; Ana C Rodriguez; Sholom Wacholder
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

9.  Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme.

Authors:  Alexander Luyten; Nina Buttmann-Schweiger; Katrin Luyten; Claudia Mauritz; Axel Reinecke-Lüthge; Martina Pietralla; Chris J L M Meijer; Karl Ulrich Petry
Journal:  Int J Cancer       Date:  2014-02-27       Impact factor: 7.396

10.  Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients.

Authors:  K-U Petry; S Menton; M Menton; F van Loenen-Frosch; H de Carvalho Gomes; B Holz; B Schopp; S Garbrecht-Buettner; P Davies; G Boehmer; E van den Akker; T Iftner
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more
  7 in total

1.  Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model.

Authors:  Jiafen Hu; Lynn R Budgeon; Nancy M Cladel; Karla Balogh; Roland Myers; Timothy K Cooper; Neil D Christensen
Journal:  J Gen Virol       Date:  2015-12       Impact factor: 3.891

2.  Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol.

Authors:  Maribel Almonte; Raúl Murillo; Gloria Inés Sánchez; Paula González; Annabelle Ferrera; María Alejandra Picconi; Carolina Wiesner; Aurelio Cruz-Valdez; Eduardo Lazcano-Ponce; Jose Jerónimo; Catterina Ferreccio; Elena Kasamatsu; Laura Mendoza; Guillermo Rodríguez; Alejandro Calderón; Gino Venegas; Verónica Villagra; Silvio Tatti; Laura Fleider; Carolina Terán; Armando Baena; María de la Luz Hernández; Mary Luz Rol; Eric Lucas; Sylvaine Barbier; Arianis Tatiana Ramírez; Silvina Arrossi; María Isabel Rodríguez; Emmanuel González; Marcela Celis; Sandra Martínez; Yuly Salgado; Marina Ortega; Andrea Verónica Beracochea; Natalia Pérez; Margarita Rodríguez de la Peña; María Ramón; Pilar Hernández-Nevarez; Margarita Arboleda-Naranjo; Yessy Cabrera; Brenda Salgado; Laura García; Marco Antonio Retana; María Celeste Colucci; Javier Arias-Stella; Yenny Bellido-Fuentes; María Liz Bobadilla; Gladys Olmedo; Ivone Brito-García; Armando Méndez-Herrera; Lucía Cardinal; Betsy Flores; Jhacquelin Peñaranda; Josefina Martínez-Better; Ana Soilán; Jacqueline Figueroa; Benedicta Caserta; Carlos Sosa; Adrián Moreno; Juan Mural; Franco Doimi; Diana Giménez; Hernando Rodríguez; Oscar Lora; Silvana Luciani; Nathalie Broutet; Teresa Darragh; Rolando Herrero
Journal:  BMJ Open       Date:  2020-05-24       Impact factor: 2.692

3.  Clinical, laboratory and epidemiological aspects of HPV infection in a low-income population from South Bahia, Brazil.

Authors:  S R Gadelha; D M V Soares-Barreto; G B Costa; V C N Leal; L G S Gomes; U R Santos; G C S Ferreira; L D Carvalho; S M V Soraes-Almeida; M A G Mello; A P M Mariano; S M B Sousa; A R Vago; L J Marin
Journal:  Epidemiol Infect       Date:  2017-11-23       Impact factor: 4.434

4.  Frequency of Human Papilloma Virus (HPV) subtypes 31,33,35,39 and 45 among Yemeni women with cervical cancer.

Authors:  Hussain Gadelkarim Ahmed; Saleh Hussein Bensumaidea; Ibraheem M Ashankyty
Journal:  Infect Agent Cancer       Date:  2015-09-07       Impact factor: 2.965

5.  Tumor-induced VEGF-C overexpression in retroperitoneal lymph nodes in VX2 carcinoma-bearing rabbits.

Authors:  Yong-Wen Huang; Yun Zhou; Chun-Yan Lan; Yin Wang; Yan-Ling Feng; Rong-Zhen Luo; Ji-Hong Liu
Journal:  Drug Des Devel Ther       Date:  2015-11-05       Impact factor: 4.162

6.  Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas.

Authors:  Céline Pinheiro; Eduardo A Garcia; Filipa Morais-Santos; Marise A R Moreira; Fábio M Almeida; Luiz F Jubé; Geraldo S Queiroz; Élbio C Paula; Maria A Andreoli; Luisa L Villa; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  BMC Cancer       Date:  2015-11-02       Impact factor: 4.430

Review 7.  The Mouse Papillomavirus Infection Model.

Authors:  Jiafen Hu; Nancy M Cladel; Lynn R Budgeon; Karla K Balogh; Neil D Christensen
Journal:  Viruses       Date:  2017-08-30       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.